Intracellular regulation of TNF activity in health and disease

Cytokine

Volumn 101, Issue , 2018, Pages 26-32

  Varfolomeev, Eugene ^a   Vucic, Domagoj ^a  

^a GENENTECH INC   (United States)

Author keywords

Apoptosis; Necroptosis; NF kB; RIP kinases; TNF; Ubiquitin

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; SUCCINATE DEHYDROGENASE (UBIQUINONE); TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2;

APOPTOSIS; ARTICLE; CELL DEATH; CELL MEMBRANE; CELL PROLIFERATION; CELL STIMULATION; CELL SURVIVAL; DISEASES; ENZYME ACTIVITY; GENE MUTATION; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; METABOLIC REGULATION; MOLECULAR BIOLOGY; NECROPTOSIS; NONHUMAN; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; TNF GENE; TNF SIGNALING; TNFR1 GENE; UBIQUITINATION; ANIMAL; CYTOPLASM; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE; PHOSPHORYLATION;

ANIMALS; APOPTOSIS; CELL DEATH; CYTOPLASM; HUMANS; MICE; NF-KAPPA B; PHOSPHORYLATION; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITINATION;

EID: 84995478858     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2016.08.035     Document Type: Article

References (130)

1. Vassalli, P., The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 10 (1992), 411–452.
2. Black, R.A., Rauch, C.T., Kozlosky, C.J., Peschon, J.J., Slack, J.L., Wolfson, M.F., Castner, B.J., Stocking, K.L., Reddy, P., Srinivasan, S., Nelson, N., Boiani, N., Schooley, K.A., Gerhart, M., Davis, R., Fitzner, J.N., Johnson, R.S., Paxton, R.J., March, C.J., Cerretti, D.P., A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385:6618 (1997), 729–733.
3. Moss, M.L., Jin, S.L., Milla, M.E., Bickett, D.M., Burkhart, W., Carter, H.L., Chen, W.J., Clay, W.C., Didsbury, J.R., Hassler, D., Hoffman, C.R., Kost, T.A., Lambert, M.H., Leesnitzer, M.A., McCauley, P., McGeehan, G., Mitchell, J., Moyer, M., Pahel, G., Rocque, W., Overton, L.K., Schoenen, F., Seaton, T., Su, J.L., Becherer, J.D., et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 385:6618 (1997), 733–736.
4. Peschon, J.J., Slack, J.L., Reddy, P., Stocking, K.L., Sunnarborg, S.W., Lee, D.C., Russell, W.E., Castner, B.J., Johnson, R.S., Fitzner, J.N., Boyce, R.W., Nelson, N., Kozlosky, C.J., Wolfson, M.F., Rauch, C.T., Cerretti, D.P., Paxton, R.J., March, C.J., Black, R.A., An essential role for ectodomain shedding in mammalian development. Science (New York, N.Y.) 282:5392 (1998), 1281–1284.
5. Reddy, P., Slack, J.L., Davis, R., Cerretti, D.P., Kozlosky, C.J., Blanton, R.A., Shows, D., Peschon, J.J., Black, R.A., Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. J. Biol. Chem. 275:19 (2000), 14608–14614.
6. Grell, M., Douni, E., Wajant, H., Lohden, M., Clauss, M., Maxeiner, B., Georgopoulos, S., Lesslauer, W., Kollias, G., Pfizenmaier, K., Scheurich, P., The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83:5 (1995), 793–802.
7. Grell, M., Becke, F.M., Wajant, H., Mannel, D.N., Scheurich, P., TNF receptor type 2 mediates thymocyte proliferation independently of TNF receptor type 1. Eur. J. Immunol. 28:1 (1998), 257–263.
8. Wallach, D., Varfolomeev, E.E., Malinin, N.L., Goltsev, Y.V., Kovalenko, A.V., Boldin, M.P., Tumor necrosis factor receptor and Fas signaling mechanisms. Annu. Rev. Immunol. 17 (1999), 331–367.
9. Sessler, T., Healy, S., Samali, A., Szegezdi, E., Structural determinants of DISC function: new insights into death receptor-mediated apoptosis signalling. Pharmacol. Ther. 140:2 (2013), 186–199.
10. Faustman, D., Davis, M., TNF receptor 2 pathway: drug target for autoimmune diseases. Nat. Rev. Drug Discovery 9:6 (2010), 482–493.
11. Pasparakis, M., Alexopoulou, L., Episkopou, V., Kollias, G., Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J. Exp. Med. 184:4 (1996), 1397–1411.
12. Marino, M.W., Dunn, A., Grail, D., Inglese, M., Noguchi, Y., Richards, E., Jungbluth, A., Wada, H., Moore, M., Williamson, B., Basu, S., Old, L.J., Characterization of tumor necrosis factor-deficient mice. Proc. Natl. Acad. Sci. USA 94:15 (1997), 8093–8098.
13. Rothe, J., Lesslauer, W., Lotscher, H., Lang, Y., Koebel, P., Kontgen, F., Althage, A., Zinkernagel, R., Steinmetz, M., Bluethmann, H., Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364:6440 (1993), 798–802.
14. Pfeffer, K., Matsuyama, T., Kundig, T.M., Wakeham, A., Kishihara, K., Shahinian, A., Wiegmann, K., Ohashi, P.S., Kronke, M., Mak, T.W., Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73:3 (1993), 457–467.
15. Erickson, S.L., de Sauvage, F.J., Kikly, K., Carver-Moore, K., Pitts-Meek, S., Gillett, N., Sheehan, K.C., Schreiber, R.D., Goeddel, D.V., Moore, M.W., Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 372:6506 (1994), 560–563.
16. Probert, L., TNF and its receptors in the CNS: the essential, the desirable and the deleterious effects. Neuroscience 302 (2015), 2–22.
17. Chan, F.K., Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling. Cytokine 37:2 (2007), 101–107.
18. Legler, D.F., Micheau, O., Doucey, M.A., Tschopp, J., Bron, C., Recruitment of TNF receptor 1 to lipid rafts is essential for TNFalpha-mediated NF-kappaB activation. Immunity 18:5 (2003), 655–664.
19. Hsu, H., Xiong, J., Goeddel, D.V., The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 81:4 (1995), 495–504.
20. Hsu, H., Huang, J., Shu, H.B., Baichwal, V., Goeddel, D.V., TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 4:4 (1996), 387–396.
21. Ting, A.T., Pimentel-Muinos, F.X., Seed, B., RIP mediates tumor necrosis factor receptor 1 activation of NF-kappaB but not Fas/APO-1-initiated apoptosis. EMBO J. 15:22 (1996), 6189–6196.
22. Hsu, H., Shu, H.B., Pan, M.G., Goeddel, D.V., TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 84:2 (1996), 299–308.
23. Rothe, M., Pan, M.G., Henzel, W.J., Ayres, T.M., Goeddel, D.V., The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 83:7 (1995), 1243–1252.
24. Shu, H.B., Takeuchi, M., Goeddel, D.V., The tumor necrosis factor receptor 2 signal transducers TRAF2 and c-IAP1 are components of the tumor necrosis factor receptor 1 signaling complex. Proc. Natl. Acad. Sci. USA 93:24 (1996), 13973–13978.
25. Park, S.M., Yoon, J.B., Lee, T.H., Receptor interacting protein is ubiquitinated by cellular inhibitor of apoptosis proteins (c-IAP1 and c-IAP2) in vitro. FEBS Lett. 566:1–3 (2004), 151–156.
26. Bertrand, M.J., Milutinovic, S., Dickson, K.M., Ho, W.C., Boudreault, A., Durkin, J., Gillard, J.W., Jaquith, J.B., Morris, S.J., Barker, P.A., CIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol. Cell 30:6 (2008), 689–700.
27. Varfolomeev, E., Goncharov, T., Fedorova, A.V., Dynek, J.N., Zobel, K., Deshayes, K., Fairbrother, W.J., Vucic, D., C-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J. Biol. Chem. 283:36 (2008), 24295–24299.
28. Wang, C., Deng, L., Hong, M., Akkaraju, G.R., Inoue, J., Chen, Z.J., TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412:6844 (2001), 346–351.
29. Kanayama, A., Seth, R.B., Sun, L., Ea, C.K., Hong, M., Shaito, A., Chiu, Y.H., Deng, L., Chen, Z.J., TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains. Mol. Cell 15:4 (2004), 535–548.
30. Tokunaga, F., Sakata, S., Saeki, Y., Satomi, Y., Kirisako, T., Kamei, K., Nakagawa, T., Kato, M., Murata, S., Yamaoka, S., Yamamoto, M., Akira, S., Takao, T., Tanaka, K., Iwai, K., Involvement of linear polyubiquitylation of NEMO in NF-kappaB activation. Nat. Cell Biol. 11:2 (2009), 123–132.
31. Haas, T.L., Emmerich, C.H., Gerlach, B., Schmukle, A.C., Cordier, S.M., Rieser, E., Feltham, R., Vince, J., Warnken, U., Wenger, T., Koschny, R., Komander, D., Silke, J., Walczak, H., Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol. Cell 36:5 (2009), 831–844.
32. Gerlach, B., Cordier, S.M., Schmukle, A.C., Emmerich, C.H., Rieser, E., Haas, T.L., Webb, A.I., Rickard, J.A., Anderton, H., Wong, W.W., Nachbur, U., Gangoda, L., Warnken, U., Purcell, A.W., Silke, J., Walczak, H., Linear ubiquitination prevents inflammation and regulates immune signalling. Nature 471:7340 (2011), 591–596.
33. Ikeda, F., Deribe, Y.L., Skanland, S.S., Stieglitz, B., Grabbe, C., Franz-Wachtel, M., van Wijk, S.J., Goswami, P., Nagy, V., Terzic, J., Tokunaga, F., Androulidaki, A., Nakagawa, T., Pasparakis, M., Iwai, K., Sundberg, J.P., Schaefer, L., Rittinger, K., Macek, B., Dikic, I., SHARPIN forms a linear ubiquitin ligase complex regulating NF-kappaB activity and apoptosis. Nature 471:7340 (2011), 637–641.
34. Tokunaga, F., Nakagawa, T., Nakahara, M., Saeki, Y., Taniguchi, M., Sakata, S., Tanaka, K., Nakano, H., Iwai, K., SHARPIN is a component of the NF-kappaB-activating linear ubiquitin chain assembly complex. Nature 471:7340 (2011), 633–636.
35. Smit, J.J., Monteferrario, D., Noordermeer, S.M., van Dijk, W.J., van der Reijden, B.A., Sixma, T.K., The E3 ligase HOIP specifies linear ubiquitin chain assembly through its RING-IBR-RING domain and the unique LDD extension. The EMBO journal 31:19 (2012), 3833–3844.
36. Draber, P., Kupka, S., Reichert, M., Draberova, H., Lafont, E., de Miguel, D., Spilgies, L., Surinova, S., Taraborrelli, L., Hartwig, T., Rieser, E., Martino, L., Rittinger, K., Walczak, H., LUBAC-recruited CYLD and A20 regulate gene activation and cell death by exerting opposing effects on linear ubiquitin in signaling complexes. Cell Reports 13:10 (2015), 2258–2272.
37. Clark, K., Nanda, S., Cohen, P., Molecular control of the NEMO family of ubiquitin-binding proteins. Nat. Rev. Mol. Cell Biol. 14:10 (2013), 673–685.
38. Zhang, S.Q., Kovalenko, A., Cantarella, G., Wallach, D., Recruitment of the IKK signalosome to the p55 TNF receptor: RIP and A20 bind to NEMO (IKKgamma) upon receptor stimulation. Immunity 12:3 (2000), 301–311.
39. Wu, C.J., Conze, D.B., Li, T., Srinivasula, S.M., Ashwell, J.D., Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-kappaB activation [corrected]. Nat. Cell Biol. 8:4 (2006), 398–406.
40. Rahighi, S., Ikeda, F., Kawasaki, M., Akutsu, M., Suzuki, N., Kato, R., Kensche, T., Uejima, T., Bloor, S., Komander, D., Randow, F., Wakatsuki, S., Dikic, I., Specific recognition of linear ubiquitin chains by NEMO is important for NF-kappaB activation. Cell 136:6 (2009), 1098–1109.
41. Dynek, J.N., Goncharov, T., Dueber, E.C., Fedorova, A.V., Izrael-Tomasevic, A., Phu, L., Helgason, E., Fairbrother, W.J., Deshayes, K., Kirkpatrick, D.S., Vucic, D., C-IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 in TNF signalling. EMBO J. 29:24 (2010), 4198–4209.
42. Ea, C.K., Deng, L., Xia, Z.P., Pineda, G., Chen, Z.J., Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol. Cell 22:2 (2006), 245–257.
43. Scheidereit, C., IkappaB kinase complexes: gateways to NF-kappaB activation and transcription. Oncogene 25:51 (2006), 6685–6705.
44. Sabio, G., Davis, R.J., TNF and MAP kinase signalling pathways. Semin. Immunol. 26:3 (2014), 237–245.
45. Kontermann, R.E., Scheurich, P., Pfizenmaier, K., Antagonists of TNF action: clinical experience and new developments. Expert Opin. Drug Discov. 4:3 (2009), 279–292.
46. Kalliolias, G.D., Ivashkiv, L.B., TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat. Rev. Rheumatol. 12:1 (2016), 49–62.
47. Wallach, D., The cybernetics of TNF: old views and newer ones. Semin. Cell Dev. Biol. 50 (2016), 105–114.
48. Harhaj, E.W., Dixit, V.M., Regulation of NF-kappaB by deubiquitinases. Immunol. Rev. 246:1 (2012), 107–124.
49. Kupka, S., Reichert, M., Draber, P., Walczak, H., Formation and removal of poly-ubiquitin chains in the regulation of TNF-induced gene activation and cell death. FEBS J., 283(14), 2016.
50. Elliott, P.R., Komander, D., Regulation of Met1-linked polyubiquitin signalling by the deubiquitinase OTULIN. FEBS J. 283:1 (2016), 39–53.
51. Pannu, J., Belle, J.I., Forster, M., Duerr, C.U., Shen, S., Kane, L., Harcourt, K., Fritz, J.H., Clare, S., Nijnik, A., Ubiquitin specific protease 21 is dispensable for normal development, hematopoiesis and lymphocyte differentiation. PLoS ONE, 10(2), 2015, e0117304.
52. Hu, H., Brittain, G.C., Chang, J.H., Puebla-Osorio, N., Jin, J., Zal, A., Xiao, Y., Cheng, X., Chang, M., Fu, Y.X., Zal, T., Zhu, C., Sun, S.C., OTUD7B controls non-canonical NF-kappaB activation through deubiquitination of TRAF3. Nature 494:7437 (2013), 371–374.
53. Wertz, I.E., O'Rourke, K.M., Zhou, H., Eby, M., Aravind, L., Seshagiri, S., Wu, P., Wiesmann, C., Baker, R., Boone, D.L., Ma, A., Koonin, E.V., Dixit, V.M., De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 430:7000 (2004), 694–699.
54. Wertz, I.E., Newton, K., Seshasayee, D., Kusam, S., Lam, C., Zhang, J., Popovych, N., Helgason, E., Schoeffler, A., Jeet, S., Ramamoorthi, N., Kategaya, L., Newman, R.J., Horikawa, K., Dugger, D., Sandoval, W., Mukund, S., Zindal, A., Martin, F., Quan, C., Tom, J., Fairbrother, W.J., Townsend, M., Warming, S., DeVoss, J., Liu, J., Dueber, E., Caplazi, P., Lee, W.P., Goodnow, C.C., Balazs, M., Yu, K., Kolumam, G., Dixit, V.M., Phosphorylation and linear ubiquitin direct A20 inhibition of inflammation. Nature 528:7582 (2015), 370–375.
55. Lee, E.G., Boone, D.L., Chai, S., Libby, S.L., Chien, M., Lodolce, J.P., Ma, A., Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science (New York, N.Y.) 289:5488 (2000), 2350–2354.
56. Zhou, Q., Wang, H., Schwartz, D.M., Stoffels, M., Park, Y.H., Zhang, Y., Yang, D., Demirkaya, E., Takeuchi, M., Tsai, W.L., Lyons, J.J., Yu, X., Ouyang, C., Chen, C., Chin, D.T., Zaal, K., Chandrasekharappa, S.C., Hanson, E.P., Yu, Z., Mullikin, J.C., Hasni, S.A., Wertz, I.E., Ombrello, A.K., Stone, D.L., Hoffmann, P., Jones, A., Barham, B.K., Leavis, H.L., van Royen-Kerkof, A., Sibley, C., Batu, E.D., Gul, A., Siegel, R.M., Boehm, M., Milner, J.D., Ozen, S., Gadina, M., Chae, J., Laxer, R.M., Kastner, D.L., Aksentijevich, I., Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nat. Genetics 48:1 (2016), 67–73.
57. Lu, T.T., Onizawa, M., Hammer, G.E., Turer, E.E., Yin, Q., Damko, E., Agelidis, A., Shifrin, N., Advincula, R., Barrera, J., Malynn, B.A., Wu, H., Ma, A., Dimerization and ubiquitin mediated recruitment of A20, a complex deubiquitinating enzyme. Immunity 38:5 (2013), 896–905.
58. De, A., Dainichi, T., Rathinam, C.V., Ghosh, S., The deubiquitinase activity of A20 is dispensable for NF-kappaB signaling. EMBO Rep. 15:7 (2014), 775–783.
59. Tokunaga, F., Nishimasu, H., Ishitani, R., Goto, E., Noguchi, T., Mio, K., Kamei, K., Ma, A., Iwai, K., Nureki, O., Specific recognition of linear polyubiquitin by A20 zinc finger 7 is involved in NF-kappaB regulation. EMBO J. 31:19 (2012), 3856–3870.
60. Brummelkamp, T.R., Nijman, S.M., Dirac, A.M., Bernards, R., Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 424:6950 (2003), 797–801.
61. Kovalenko, A., Chable-Bessia, C., Cantarella, G., Israel, A., Wallach, D., Courtois, G., The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 424:6950 (2003), 801–805.
62. Trompouki, E., Hatzivassiliou, E., Tsichritzis, T., Farmer, H., Ashworth, A., Mosialos, G., CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 424:6950 (2003), 793–796.
63. Wright, A., Reiley, W.W., Chang, M., Jin, W., Lee, A.J., Zhang, M., Sun, S.C., Regulation of early wave of germ cell apoptosis and spermatogenesis by deubiquitinating enzyme CYLD. Dev. Cell 13:5 (2007), 705–716.
64. Massoumi, R., Chmielarska, K., Hennecke, K., Pfeifer, A., Fassler, R., Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 125:4 (2006), 665–677.
65. Zhang, J., Stirling, B., Temmerman, S.T., Ma, C.A., Fuss, I.J., Derry, J.M., Jain, A., Impaired regulation of NF-kappaB and increased susceptibility to colitis-associated tumorigenesis in CYLD-deficient mice. J. Clin. Invest. 116:11 (2006), 3042–3049.
66. Nikolaou, K., Tsagaratou, A., Eftychi, C., Kollias, G., Mosialos, G., Talianidis, I., Inactivation of the deubiquitinase CYLD in hepatocytes causes apoptosis, inflammation, fibrosis, and cancer. Cancer Cell 21:6 (2012), 738–750.
67. Keusekotten, K., Elliott, P.R., Glockner, L., Fiil, B.K., Damgaard, R.B., Kulathu, Y., Wauer, T., Hospenthal, M.K., Gyrd-Hansen, M., Krappmann, D., Hofmann, K., Komander, D., OTULIN antagonizes LUBAC signaling by specifically hydrolyzing Met1-linked polyubiquitin. Cell 153:6 (2013), 1312–1326.
68. Rivkin, E., Almeida, S.M., Ceccarelli, D.F., Juang, Y.C., MacLean, T.A., Srikumar, T., Huang, H., Dunham, W.H., Fukumura, R., Xie, G., Gondo, Y., Raught, B., Gingras, A.C., Sicheri, F., Cordes, S.P., The linear ubiquitin-specific deubiquitinase gumby regulates angiogenesis. Nature 498:7454 (2013), 318–324.
69. Schaeffer, V., Akutsu, M., Olma, M.H., Gomes, L.C., Kawasaki, M., Dikic, I., Binding of OTULIN to the PUB domain of HOIP controls NF-kappaB signaling. Mol. Cell 54:3 (2014), 349–361.
70. Takiuchi, T., Nakagawa, T., Tamiya, H., Fujita, H., Sasaki, Y., Saeki, Y., Takeda, H., Sawasaki, T., Buchberger, A., Kimura, T., Iwai, K., Suppression of LUBAC-mediated linear ubiquitination by a specific interaction between LUBAC and the deubiquitinases CYLD and OTULIN. Genes Cells: Devoted Mol. Cell. Mech. 19:3 (2014), 254–272.
71. Zhou, Q., Yu, X., Demirkaya, E., Deuitch, N., Stone, D., Tsai, W.L., Kuehn, H.S., Wang, H., Yang, D., Park, Y.H., Ombrello, A.K., Blake, M., Romeo, T., Remmers, E.F., Chae, J.J., Mullikin, J.C., Guzel, F., Milner, J.D., Boehm, M., Rosenzweig, S.D., Gadina, M., Welch, S.B., Ozen, S., Topaloglu, R., Abinun, M., Kastner, D.L., Aksentijevich, I., Biallelic hypomorphic mutations in a linear deubiquitinase define otulipenia, an early-onset autoinflammatory disease. Proc. Natl. Acad. Sci. USA, 2016 [Epub ahead of print].
72. Damgaard, R.B., Walker, J.A., Marco-Casanova, P., Morgan, N.V., Titheradge, H.L., Elliott, P.R., McHale, D., Maher, E.R., McKenzie, A.N., Komander, D., The deubiquitinase OTULIN is an essential negative regulator of inflammation and autoimmunity. Cell 166:5 (2016), 1215–1230.
73. Ashkenazi, A., Salvesen, G., Regulated cell death: signaling and mechanisms. Annu. Rev. Cell Dev. Biol. 30 (2014), 337–356.
74. Shalini, S., Dorstyn, L., Dawar, S., Kumar, S., Old, new and emerging functions of caspases. Cell Death Differ. 22:4 (2015), 526–539.
75. Tsuchiya, Y., Nakabayashi, O., Nakano, H., FLIP the switch: regulation of apoptosis and necroptosis by cFLIP. Int. J. Mol. Sci. 16:12 (2015), 30321–30341.
76. Pobezinskaya, Y.L., Kim, Y.S., Choksi, S., Morgan, M.J., Li, T., Liu, C., Liu, Z., The function of TRADD in signaling through tumor necrosis factor receptor 1 and TRIF-dependent Toll-like receptors. Nat. Immunol. 9:9 (2008), 1047–1054.
77. Wang, L., Du, F., Wang, X., TNF-alpha induces two distinct caspase-8 activation pathways. Cell 133:4 (2008), 693–703.
78. Kelliher, M.A., Grimm, S., Ishida, Y., Kuo, F., Stanger, B.Z., Leder, P., The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity 8:3 (1998), 297–303.
79. Karin, M., Lin, A., NF-kappaB at the crossroads of life and death. Nat. Immunol. 3:3 (2002), 221–227.
80. Cheung, H.H., Mahoney, D.J., Lacasse, E.C., Korneluk, R.G., Down-regulation of c-FLIP enhances death of cancer cells by smac mimetic compound. Cancer Res. 69:19 (2009), 7729–7738.
81. Tanaka, M., Fuentes, M.E., Yamaguchi, K., Durnin, M.H., Dalrymple, S.A., Hardy, K.L., Goeddel, D.V., Embryonic lethality, liver degeneration, and impaired NF-kappa B activation in IKK-beta-deficient mice. Immunity 10:4 (1999), 421–429.
82. Li, Q., Van Antwerp, D., Mercurio, F., Lee, K.F., Verma, I.M., Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science (New York, N.Y.) 284:5412 (1999), 321–325.
83. Beg, A.A., Sha, W.C., Bronson, R.T., Ghosh, S., Baltimore, D., Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature 376:6536 (1995), 167–170.
84. Alcamo, E., Mizgerd, J.P., Horwitz, B.H., Bronson, R., Beg, A.A., Scott, M., Doerschuk, C.M., Hynes, R.O., Baltimore, D., Targeted mutation of TNF receptor I rescues the RelA-deficient mouse and reveals a critical role for NF-kappa B in leukocyte recruitment. J. Immunol. (Baltimore, Md.: 1950) 167:3 (2001), 1592–1600.
85. Newton, K., Manning, G., Necroptosis and inflammation. Annu. Rev. Biochem. 85 (2016), 743–763.
86. Vandenabeele, P., Galluzzi, L., Vanden Berghe, T., Kroemer, G., Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat. Rev. Mol. Cell Biol. 11:10 (2010), 700–714.
87. Sun, X., Yin, J., Starovasnik, M.A., Fairbrother, W.J., Dixit, V.M., Identification of a novel homotypic interaction motif required for the phosphorylation of receptor-interacting protein (RIP) by RIP3. J. Biol. Chem. 277:11 (2002), 9505–9511.
88. Vandenabeele, P., Declercq, W., Van Herreweghe, F., Vanden Berghe, T., The role of the kinases RIP1 and RIP3 in TNF-induced necrosis. Sci. Signaling, 3(115), 2010, re4.
89. Cho, Y.S., Challa, S., Moquin, D., Genga, R., Ray, T.D., Guildford, M., Chan, F.K., Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 137:6 (2009), 1112–1123.
90. He, S., Wang, L., Miao, L., Wang, T., Du, F., Zhao, L., Wang, X., Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell 137:6 (2009), 1100–1111.
91. Vanlangenakker, N., Vanden Berghe, T., Bogaert, P., Laukens, B., Zobel, K., Deshayes, K., Vucic, D., Fulda, S., Vandenabeele, P., Bertrand, M.J., cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-dependent reactive oxygen species production. Cell Death Differ. 18:4 (2011), 656–665.
92. Degterev, A., Hitomi, J., Germscheid, M., Ch'en, I.L., Korkina, O., Teng, X., Abbott, D., Cuny, G.D., Yuan, C., Wagner, G., Hedrick, S.M., Gerber, S.A., Lugovskoy, A., Yuan, J., Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat. Chem. Biol. 4:5 (2008), 313–321.
93. Newton, K., Dugger, D.L., Wickliffe, K.E., Kapoor, N., de Almagro, M.C., Vucic, D., Komuves, L., Ferrando, R.E., French, D.M., Webster, J., Roose-Girma, M., Warming, S., Dixit, V.M., Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis. Science (New York, N.Y.) 343:6177 (2014), 1357–1360.
94. Kaiser, W.J., Sridharan, H., Huang, C., Mandal, P., Upton, J.W., Gough, P.J., Sehon, C.A., Marquis, R.W., Bertin, J., Mocarski, E.S., Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J. Biol. Chem. 288:43 (2013), 31268–31279.
95. Zhao, J., Jitkaew, S., Cai, Z., Choksi, S., Li, Q., Luo, J., Liu, Z.G., Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis. Proc. Natl. Acad. Sci. USA 109:14 (2012), 5322–5327.
96. Sun, L., Wang, H., Wang, Z., He, S., Chen, S., Liao, D., Wang, L., Yan, J., Liu, W., Lei, X., Wang, X., Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 148:1–2 (2012), 213–227.
97. Wang, H., Sun, L., Su, L., Rizo, J., Liu, L., Wang, L.F., Wang, F.S., Wang, X., Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Mol. Cell 54:1 (2014), 133–146.
98. Cai, Z., Jitkaew, S., Zhao, J., Chiang, H.C., Choksi, S., Liu, J., Ward, Y., Wu, L.G., Liu, Z.G., Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis. Nat. Cell Biol. 16:1 (2014), 55–65.
99. Dondelinger, Y., Declercq, W., Montessuit, S., Roelandt, R., Goncalves, A., Bruggeman, I., Hulpiau, P., Weber, K., Sehon, C.A., Marquis, R.W., Bertin, J., Gough, P.J., Savvides, S., Martinou, J.C., Bertrand, M.J., Vandenabeele, P., MLKL compromises plasma membrane integrity by binding to phosphatidylinositol phosphates. Cell Reports 7:4 (2014), 971–981.
100. Petersen, S.L., Wang, L., Yalcin-Chin, A., Li, L., Peyton, M., Minna, J., Harran, P., Wang, X., Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 12:5 (2007), 445–456.
101. Gaither, A., Porter, D., Yao, Y., Borawski, J., Yang, G., Donovan, J., Sage, D., Slisz, J., Tran, M., Straub, C., Ramsey, T., Iourgenko, V., Huang, A., Chen, Y., Schlegel, R., Labow, M., Fawell, S., Sellers, W.R., Zawel, L., A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling. Cancer Res. 67:24 (2007), 11493–11498.
102. O'Donnell, M.A., Legarda-Addison, D., Skountzos, P., Yeh, W.C., Ting, A.T., Ubiquitination of RIP1 regulates an NF-kappaB-independent cell-death switch in TNF signaling. Curr. Biol.: CB 17:5 (2007), 418–424.
103. Moulin, M., Anderton, H., Voss, A.K., Thomas, T., Wong, W.W., Bankovacki, A., Feltham, R., Chau, D., Cook, W.D., Silke, J., Vaux, D.L., IAPs limit activation of RIP kinases by TNF receptor 1 during development. EMBO J. 31:7 (2012), 1679–1691.
104. Silke, J., Vaux, D.L., IAP gene deletion and conditional knockout models. Semin. Cell Dev. Biol. 39 (2015), 97–105.
105. Peltzer, N., Rieser, E., Taraborrelli, L., Draber, P., Darding, M., Pernaute, B., Shimizu, Y., Sarr, A., Draberova, H., Montinaro, A., Martinez-Barbera, J.P., Silke, J., Rodriguez, T.A., Walczak, H., HOIP deficiency causes embryonic lethality by aberrant TNFR1-mediated endothelial cell death. Cell Reports 9:1 (2014), 153–165.
106. Boisson, B., Laplantine, E., Dobbs, K., Cobat, A., Tarantino, N., Hazen, M., Lidov, H.G., Hopkins, G., Du, L., Belkadi, A., Chrabieh, M., Itan, Y., Picard, C., Fournet, J.C., Eibel, H., Tsitsikov, E., Pai, S.Y., Abel, L., Al-Herz, W., Casanova, J.L., Israel, A., Notarangelo, L.D., Human HOIP and LUBAC deficiency underlies autoinflammation, immunodeficiency, amylopectinosis, and lymphangiectasia. J. Exp. Med. 212:6 (2015), 939–951.
107. Boisson, B., Laplantine, E., Prando, C., Giliani, S., Israelsson, E., Xu, Z., Abhyankar, A., Israel, L., Trevejo-Nunez, G., Bogunovic, D., Cepika, A.M., MacDuff, D., Chrabieh, M., Hubeau, M., Bajolle, F., Debre, M., Mazzolari, E., Vairo, D., Agou, F., Virgin, H.W., Bossuyt, X., Rambaud, C., Facchetti, F., Bonnet, D., Quartier, P., Fournet, J.C., Pascual, V., Chaussabel, D., Notarangelo, L.D., Puel, A., Israel, A., Casanova, J.L., Picard, C., Immunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency. Nat. Immunol. 13:12 (2012), 1178–1186.
108. Seymour, R.E., Hasham, M.G., Cox, G.A., Shultz, L.D., Hogenesch, H., Roopenian, D.C., Sundberg, J.P., Spontaneous mutations in the mouse Sharpin gene result in multiorgan inflammation, immune system dysregulation and dermatitis. Genes Immun. 8:5 (2007), 416–421.
109. Kumari, S., Redouane, Y., Lopez-Mosqueda, J., Shiraishi, R., Romanowska, M., Lutzmayer, S., Kuiper, J., Martinez, C., Dikic, I., Pasparakis, M., Ikeda, F., Sharpin prevents skin inflammation by inhibiting TNFR1-induced keratinocyte apoptosis. eLife, 3, 2014.
110. Rickard, J.A., Anderton, H., Etemadi, N., Nachbur, U., Darding, M., Peltzer, N., Lalaoui, N., Lawlor, K.E., Vanyai, H., Hall, C., Bankovacki, A., Gangoda, L., Wong, W.W., Corbin, J., Huang, C., Mocarski, E.S., Murphy, J.M., Alexander, W.S., Voss, A.K., Vaux, D.L., Kaiser, W.J., Walczak, H., Silke, J., TNFR1-dependent cell death drives inflammation in Sharpin-deficient mice. eLife, 3, 2014.
111. Berger, S.B., Kasparcova, V., Hoffman, S., Swift, B., Dare, L., Schaeffer, M., Capriotti, C., Cook, M., Finger, J., Hughes-Earle, A., Harris, P.A., Kaiser, W.J., Mocarski, E.S., Bertin, J., Gough, P.J., Cutting Edge: RIP1 kinase activity is dispensable for normal development but is a key regulator of inflammation in SHARPIN-deficient mice. J. Immunol. (Baltimore, Md.: 1950) 192:12 (2014), 5476–5480.
112. Rudolph, D., Yeh, W.C., Wakeham, A., Rudolph, B., Nallainathan, D., Potter, J., Elia, A.J., Mak, T.W., Severe liver degeneration and lack of NF-kappaB activation in NEMO/IKKgamma-deficient mice. Genes Dev. 14:7 (2000), 854–862.
113. Cubero, F.J., Singh, A., Borkham-Kamphorst, E., Nevzorova, Y.A., Al Masaoudi, M., Haas, U., Boekschoten, M.V., Gassler, N., Weiskirchen, R., Muller, M., Liedtke, C., Trautwein, C., TNFR1 determines progression of chronic liver injury in the IKKgamma/Nemo genetic model. Cell Death Differ. 20:11 (2013), 1580–1592.
114. Ehlken, H., Krishna-Subramanian, S., Ochoa-Callejero, L., Kondylis, V., Nadi, N.E., Straub, B.K., Schirmacher, P., Walczak, H., Kollias, G., Pasparakis, M., Death receptor-independent FADD signalling triggers hepatitis and hepatocellular carcinoma in mice with liver parenchymal cell-specific NEMO knockout. Cell Death Differ. 21:11 (2014), 1721–1732.
115. Liedtke, C., Bangen, J.M., Freimuth, J., Beraza, N., Lambertz, D., Cubero, F.J., Hatting, M., Karlmark, K.R., Streetz, K.L., Krombach, G.A., Tacke, F., Gassler, N., Riethmacher, D., Trautwein, C., Loss of caspase-8 protects mice against inflammation-related hepatocarcinogenesis but induces non-apoptotic liver injury. Gastroenterology 141:6 (2011), 2176–2187.
116. Kondylis, V., Polykratis, A., Ehlken, H., Ochoa-Callejero, L., Straub, B.K., Krishna-Subramanian, S., Van, T.M., Curth, H.M., Heise, N., Weih, F., Klein, U., Schirmacher, P., Kelliher, M., Pasparakis, M., NEMO prevents steatohepatitis and hepatocellular carcinoma by inhibiting RIPK1 kinase activity-mediated hepatocyte apoptosis. Cancer Cell 28:5 (2015), 582–598.
117. Nenci, A., Becker, C., Wullaert, A., Gareus, R., van Loo, G., Danese, S., Huth, M., Nikolaev, A., Neufert, C., Madison, B., Gumucio, D., Neurath, M.F., Pasparakis, M., Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 446:7135 (2007), 557–561.
118. Vlantis, K., Wullaert, A., Polykratis, A., Kondylis, V., Dannappel, M., Schwarzer, R., Welz, P., Corona, T., Walczak, H., Weih, F., Klein, U., Kelliher, M., Pasparakis, M., NEMO prevents RIP kinase 1-mediated epithelial cell death and chronic intestinal inflammation by NF-kappaB-dependent and -independent functions. Immunity 44:3 (2016), 553–567.
119. Kawai, T., Nishikomori, R., Heike, T., Diagnosis and treatment in anhidrotic ectodermal dysplasia with immunodeficiency. Allergol. Int.: Off. J. Jpn. Soc. Allergol. 61:2 (2012), 207–217.
120. Courtois, G., Gilmore, T.D., Mutations in the NF-kappaB signaling pathway: implications for human disease. Oncogene 25:51 (2006), 6831–6843.
121. Makris, C., Godfrey, V.L., Krahn-Senftleben, G., Takahashi, T., Roberts, J.L., Schwarz, T., Feng, L., Johnson, R.S., Karin, M., Female mice heterozygous for IKK gamma/NEMO deficiencies develop a dermatopathy similar to the human X-linked disorder incontinentia pigmenti. Mol. Cell 5:6 (2000), 969–979.
122. Schmidt-Supprian, M., Bloch, W., Courtois, G., Addicks, K., Israel, A., Rajewsky, K., Pasparakis, M., NEMO/IKK gamma-deficient mice model incontinentia pigmenti. Mol. Cell 5:6 (2000), 981–992.
123. Nenci, A., Huth, M., Funteh, A., Schmidt-Supprian, M., Bloch, W., Metzger, D., Chambon, P., Rajewsky, K., Krieg, T., Haase, I., Pasparakis, M., Skin lesion development in a mouse model of incontinentia pigmenti is triggered by NEMO deficiency in epidermal keratinocytes and requires TNF signaling. Hum. Mol. Genet. 15:4 (2006), 531–542.
124. Dondelinger, Y., Jouan-Lanhouet, S., Divert, T., Theatre, E., Bertin, J., Gough, P.J., Giansanti, P., Heck, A.J., Dejardin, E., Vandenabeele, P., Bertrand, M.J., NF-kappaB-independent role of IKKalpha/IKKbeta in preventing RIPK1 kinase-dependent apoptotic and necroptotic cell death during TNF signaling. Mol. Cell 60:1 (2015), 63–76.
125. Reiley, W., Zhang, M., Wu, X., Granger, E., Sun, S.C., Regulation of the deubiquitinating enzyme CYLD by IkappaB kinase gamma-dependent phosphorylation. Mol. Cell. Biol. 25:10 (2005), 3886–3895.
126. O'Donnell, M.A., Perez-Jimenez, E., Oberst, A., Ng, A., Massoumi, R., Xavier, R., Green, D.R., Ting, A.T., Caspase 8 inhibits programmed necrosis by processing CYLD. Nat. Cell Biol. 13:12 (2011), 1437–1442.
127. Yeh, W.C., Itie, A., Elia, A.J., Ng, M., Shu, H.B., Wakeham, A., Mirtsos, C., Suzuki, N., Bonnard, M., Goeddel, D.V., Mak, T.W., Requirement for Casper (c-FLIP) in regulation of death receptor-induced apoptosis and embryonic development. Immunity 12:6 (2000), 633–642.
128. Oberst, A., Dillon, C.P., Weinlich, R., McCormick, L.L., Fitzgerald, P., Pop, C., Hakem, R., Salvesen, G.S., Green, D.R., Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 471:7338 (2011), 363–367.
129. Feng, S., Yang, Y., Mei, Y., Ma, L., Zhu, D.E., Hoti, N., Castanares, M., Wu, M., Cleavage of RIP3 inactivates its caspase-independent apoptosis pathway by removal of kinase domain. Cell. Signal. 19:10 (2007), 2056–2067.
130. Dillon, C.P., Oberst, A., Weinlich, R., Janke, L.J., Kang, T.B., Ben-Moshe, T., Mak, T.W., Wallach, D., Green, D.R., Survival function of the FADD-CASPASE-8-cFLIP(L) complex. Cell Reports 1:5 (2012), 401–407.